Reducing bleeding complications after thrombolytic therapy for stroke: Clinical potential of metalloproteinase inhibitors and spin trap agents

CNS Drugs

Volumn 15, Issue 11, 2001, Pages 819-829

  Lapchak, Paul A ^a,b,c   Araujo, Dalia M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BATIMASTAT; BB 2284; CD18 ANTIGEN; CYCLOOXYGENASE 2; FREE RADICAL; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; N TERT BUTYL ALPHA PHENYLNITRONE; NITRIC OXIDE SYNTHASE; SCAVENGER; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; FIBRINOLYTIC THERAPY; HIGH RISK POPULATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; SPIN TRAPPING; STROKE; THROMBOSIS;

ANIMALS; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; HUMANS; MATRIX METALLOPROTEINASES; SPIN LABELS; SPIN TRAPPING; SUBARACHNOID HEMORRHAGE; THROMBOLYTIC THERAPY;

EID: 0035215147     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115110-00001     Document Type: Review

References (74)

1. The Harvard Cooperative Stroke Registry: A prospective registry
2. Intracerebral hemorrhage: An update
3. Surgery for intracerebral hemorrhage
4. Hemorrhagic transformation in cerebral embolism
5. Hemorrhagic transformation in cardioembolic cerebral infarction
6. Hemorrhagic transformation of brain infarct: Predictability in the first 5 hours from stroke onset and influence on clinical outcome
7. Measurements of acute cerebral infarction: A clinical examination scale
8. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction
9. Hemorrhagic transformation after cerebral ischemia: Mechanisms and incidence
10. Surgical treatment for intracerebral hemorrhage (STICH): A single-center, randomized clinical trial
11. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
12. Hemorrhagic transformations in acute ischemic stroke. The MAST-E study. MAST-E group
13. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Stroke Study (ECASS)
14. Thrombolytic stroke therapy: Past, present, and future
15. Microvascular responses to cerebral ischemia/inflammation
16. tPA-associated reperfusion after acute stroke demonstrated by SPECT
17. Open label tissue plasminogen activator for stroke: The Oregon experience
18. Reperfusion injury after focal cerebral ischemia: The role of inflammation and the therapeutic horizon
19. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue
20. Hyperacute stroke therapy with tissue plasminogen activator
21. tPA in acute ischemic stroke. United States experience and issues for the future
22. Diagnosis and treatment of ischemic stroke
23. Tissue plasminogen activator for acute ischemic stroke
24. Risk-benefit of thrombolysis
25. Intravenous thrombolytic therapy for stroke: A review of recent studies and controversies
26. Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration
27. Trends and future developments in the pharmacological treatment of acute ischaemic stroke
28. Does neuroprotection improve stroke outcome?
29. Neuroprotection for acute stroke: Making clinical trials work
30. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
31. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic model. Combination studies with the thrombolytic tissue plasminogen activator
32. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat
33. Calcium and ischemic injury
34. (S)-Emopamil reduces brain edema from collagenase-induced hemorrhage in rats
35. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to the rat brain: Activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures
36. Free radicals as mediators of neuronal injury
37. Mechanisms of secondary brain injury
38. Matrix metalloproteinases in brain injury
39. Extracellular matrix-degrading proteinases in the nervous system
40. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size
41. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia
42. Vascular extracellular matrix remodeling in cerebral aneurysms
43. Processing of tumour necrosis factor-α precursor by metalloproteinases
44. Inhibition of matrix metalloproteinases: Structure based design
45. Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing
46. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor
47. Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP
48. Tumor necrosis factor-alpha: A mediator of focal ischemic brain injury
49. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
50. Matrix metalloproteinases in cerebrovascular disease
51. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window
52. Redaction of intracerebral hemorrhaging in a rabbit embolic stroke model
53. Extracellular matrix degradation by metalloproteinases and central nervous system diseases
54. Ischemic brain edema
55. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat
56. Antioxidants, oxidative stress, and degenerative neurological disorders
57. Free radical spin traps as adjuncts for the prevention and treatment of disease
58. Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies
59. PBN spin trapping of free radicals in the reperfusion-injured heart. Limitations for pharmacological investigations
60. Inhibition of NF-kappaB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-N-butylnitrone (PBN)
61. Spin trap (N-t-butyl-alpha-phenylnitrone)-mediated suprainduction of heme oxygenase-1 in kidney ischemia/reperfusion model: Role of the oxygenase in protection against oxidative injury
62. Nitric oxide formation during light-induced decomposition of phenyl N-tert-butylnitrone
63. Nitrone spin traps block calcium channels and induce pulmonary artery relaxation independent of free radicals
64. Blood chemistry changes in the rat induced by high doses of nitronyl free radical spin traps
65. Excretion, metabolism and tissue distribution of a spin trapping agent, alpha-phenyl-N-tert-butyl-nitrone (PBN) in rats
66. N-tert-butyl-alpha-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia
67. Delayed treatment with α-phenyl-N-tert-butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat
68. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
69. Neuroprotective effects of the novel brain-penetrating antioxidant U-101033E and the spin-trapping agent alpha-phenyl-N-tert-butyl nitrone (PBN)
70. Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat
71. Protective effects of free radical inhibitors in intracerebral hemorrhage in rat
72. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats
73. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps
74. Facilitation of post-ischemic reperfusion with alpha-PBN: Assessment using NMR and Doppler flow techniques